Real World Early Physician Experience Using an Intracanalicular Dexamethasone Insert to Treat Post-Operative Ocular Inflammation and Pain

John D. Stephens, MD; Jay C. Bradley, MD, Brian B. Foster, MD; Richard A. Lehrer, MD; Alyssa M. Montieth; Srilatha Vantipalli, PhD; Jamie Lynne Metzinger, MPH; Michael H. Goldstein, MD, MBA

ASCRS ANNUAL MEETING | JULY 23-27, 2021 | LAS VEGAS, NV

FINANCIAL DISCLOSURES

John D. Stephens, MD (Presenting Author), Jay C. Bradley, MD, Brian B. Foster, MD, and Richard A. Lehrer, MD, were participants in the surveys.

Alyssa M. Montieth; Srilatha Vantipalli, PhD; Jamie Lynne Metzinger, MPH; and Michael H. Goldstein, MD, MBA are employees of Ocular Therapeutix, Inc.

This research was funded by Ocular Therapeutix, Inc.

Study support and data collection was provided by Clinical SCORE, LLC

Introduction and Rationale

DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg

- Intracanalicular, sustained-release, bioresorbable, hydrogel-based insert that releases dexamethasone over 4-weeks¹
- FDA-approved for treating of ocular inflammation and pain following ophthalmic surgery¹
- The Early Experience Program collected initial user experience and feedback with DEXTENZA in cataract surgery patients

Due to structural and physical differences between punctal/canalicular plugs and DEXTENZA, we aimed to evaluate the learning curve for the administration of DEXTENZA





Activates:1,2

- With moisture
- Swells to fit in the canaliculus

Releases:^{1,2}

 Dexamethasone for up to 30 days

Resorbs:^{1,2}

- Slowly through the course of treatment
- Clears via the nasolacrimal duct

References: 1. DEXTENZA [package insert]. Bedford, MA: Ocular Therapeutix, Inc; June 2019. 2. Walters T, et al. J Clin Exp Ophthalmol. 2016;7(4):1-11.

Methods: Study Design

Phase 4 Experiential Cross-Sectional Survey Study


Survey Respondents

- Physicians who participated in the Early Experience Program with no prior experience using DEXTENZA in cataract surgery patients
- Represented 23 US practices, including ambulatory surgical clinical settings and outpatient clinical settings


Data Analysis

- Descriptive statistics summarized responses to determine:
 - Number of insertions required before becoming comfortable
 - Incremental burden on staff time and logistics
 - Overall physician satisfaction


The study was comprised of 3 sequential online physician surveys




Physician Demographics




On Average, Physicians were Comfortable Placing DEXTENZA After 3 Inserts Overall, 90% of physicians were comfortable using DEXTENZA






*Physicians were asked to rate their overall comfort with DEXTENZA on a Likert scale of 1 (not comfortable) to 7 (very comfortable) one day after performing cataract surgery

87% of Physicians Rated Their Experience with DEXTENZA as Easy and Estimated Little to No Burden on Staff



Overall, 91% of Physicians were Satisfied with DEXTENZA



Conclusions

DEXTENZA appears to integrate well into clinical use



On average, physicians with no prior experience using DEXTENZA in cataract surgery patients reported becoming **comfortable with inserting DEXTENZA after 3 insertions** regardless of clinical setting



Most physicians (87%) thought that the experience of **using DEXTENZA was easy** and created **little to no incremental burden** on staff time and logistics use



A majority (91%) of physicians new to DEXTENZA reported overall satisfaction with DEXTENZA